Malignant neoplasm of fundus of stomach
ICD-10 C16.1 is a billable code used to indicate a diagnosis of malignant neoplasm of fundus of stomach.
C16.1 refers to a malignant neoplasm located specifically in the fundus of the stomach, which is the uppermost part of the stomach. Gastric cancer, particularly in this region, is often associated with chronic infection by Helicobacter pylori (H. pylori), a bacterium that can lead to chronic gastritis and is a significant risk factor for the development of gastric adenocarcinoma. The pathophysiology involves the transformation of gastric epithelial cells due to prolonged inflammation and genetic mutations. Staging of gastric cancer is crucial for determining treatment options and prognosis, typically classified using the TNM system (Tumor, Node, Metastasis). Treatment often involves surgical intervention, such as gastrectomy, which may be partial or total depending on the extent of the disease. Postoperative care and monitoring for recurrence are essential components of management. Accurate coding for C16.1 requires thorough documentation of the diagnosis, staging, and any surgical procedures performed.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis of gastric cancer, staging evaluations, and treatment planning.
Ensure accurate documentation of tumor characteristics and treatment response.
Endoscopy reports, biopsy results, and H. pylori testing.
Management of gastric ulcers, chronic gastritis, and screening for gastric cancer.
Document any findings related to H. pylori and its treatment.
Used for patients diagnosed with malignant neoplasm of the fundus of the stomach.
Operative report detailing the procedure and findings.
Oncology and surgery specialties must coordinate documentation.
H. pylori infection is a major risk factor for gastric cancer, particularly adenocarcinoma. It causes chronic inflammation and can lead to changes in the gastric epithelium, increasing the risk of malignant transformation.
